Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis

2016 ◽  
Vol 36 (8) ◽  
pp. 870-879 ◽  
Author(s):  
Paweł Moćko ◽  
Paweł Kawalec ◽  
Andrzej Pilc
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Safety Profile ◽  
Meta Analysis ◽  
Biologic Drugs

scholarly journals Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2159
Author(s):  
Charalampos Aktypis ◽  
Maria-Eleni Spei ◽  
Maria Yavropoulou ◽  
Göran Wallin ◽  
Anna Koumarianou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Adverse Effects ◽  
Targeted Therapies ◽  
Safety Profile ◽  
Meta Analysis ◽  
Mtor Inhibitors ◽  
Risk Of Bias ◽  
Neuroendocrine Neoplasms ◽  
Controlled Trials

A broad spectrum of novel targeted therapies with prime antitumor activity and/or ample control of hormonal symptoms together with an overall acceptable safety profile have emerged for patients with metastatic neuroendocrine neoplasms (NENs). In this systematic review and quantitative meta-analysis, the PubMed, EMBASE, Cochrane Central Register of Controlled Trials and clinicaltrials.gov databases were searched to assess and compare the safety profile of NEN treatments with special focus on the cardiovascular adverse effects of biotherapy and molecular targeted therapies (MTTs). Quality/risk of bias were assessed using GRADE criteria. Placebo-controlled randomized clinical trials (RCTs) in patients with metastatic NENs, including medullary thyroid cancer (MTC) were included. A total of 3695 articles and 122 clinical trials registered in clinicaltrials.gov were screened. We included sixteen relevant RCTs comprising 3408 unique patients assigned to different treatments compared with placebo. All the included studies had a low risk of bias. We identified four drug therapies for NENs with eligible placebo-controlled RCTs: somatostatin analogs (SSAs), tryptophan hydroxylase (TPH) inhibitors, mTOR inhibitors and tyrosine kinase inhibitors (TKI). Grade 3 and 4 adverse effects (AE) were more often encountered in patients treated with mTOR inhibitors and TKI (odds ratio [OR]: 2.42, 95% CI: 1.87–3.12 and OR: 3.41, 95% CI: 1.46–7.96, respectively) as compared to SSAs (OR:0.77, 95% CI: 0.47–1.27) and TPH inhibitors (OR:0.77, 95% CI: 0.35–1.69). MTOR inhibitors had the highest risk for serious cardiac AE (OR:3.28, 95% CI: 1.66–6.48) followed by TKIs (OR:1.51, 95% CI: 0.59–3.83). Serious vascular AE were more often encountered in NEN patients treated with mTOR inhibitors (OR: 1.72, 95% CI: 0.64–4.64) and TKIs (OR:1.64, 95% CI: 0.35–7.78). Finally, patients on TKIs were at higher risk for new-onset or exacerbation of pre-existing hypertension (OR:3.31, 95% CI: 1.87–5.86). In conclusion, SSAs and TPH inhibitors appear to be safer as compared to mTOR inhibitors and TKIs with regards to their overall toxicity profile, and cardiovascular toxicities in particular. Special consideration should be given to a patient-tailored approach with anticipated toxicities of targeted NEN treatments together with assessment of cardiovascular comorbidities, assisting clinicians in treatment selection and early recognition/management of cardiovascular toxicities. This approach could improve patient compliance and preserve cardiovascular health and overall quality of life.

Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis

2011 ◽  
Vol 106 (4) ◽  
pp. 601-616 ◽  
Author(s):  
Alexander C Ford ◽  
Jean-Paul Achkar ◽  
Khurram J Khan ◽  
Sunanda V Kane ◽  
Nicholas J Talley ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Meta Analysis

Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis

2018 ◽  
Vol 40 (6) ◽  
pp. 1411-1419 ◽  
Author(s):  
Cristina Trigo-Vicente ◽  
Vicente Gimeno-Ballester ◽  
Santiago García-López ◽  
Alejandro López-Del Val
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Meta Analysis ◽  
Severe Ulcerative Colitis

Biologic Drugs in Crohn';s Disease and Ulcerative Colitis: Safety Profile

2016 ◽  
Vol 11 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Antonio Di Sario ◽  
Emanuele Bendia ◽  
Laura Schiadà ◽  
Paola Sassaroli ◽  
Antonio Benedetti
Keyword(s):  
Ulcerative Colitis ◽  
Safety Profile ◽  
Biologic Drugs

Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis

2019 ◽  
Vol 17 (3) ◽  
pp. 411-418.e3 ◽  
Author(s):  
Neeraj Narula ◽  
Abdul-Aziz Alshahrani ◽  
Yuhong Yuan ◽  
Walter Reinisch ◽  
Jean-Frederic Colombel
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Patient Reported Outcomes ◽  
Meta Analysis ◽  
Endoscopic Appearance ◽  
Patient Reported

scholarly journals Efficacy and safety of Shenling Atractylodes Powder in the treatment of ulcerative colitis: a systematic review and Meta analysis

2021 ◽  
Author(s):  
Quanhui Zhang ◽  
Yongwen Deng ◽  
Jinlong Wang ◽  
Feihong Huang ◽  
Yiduo Zhou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ulcerative Colitis ◽  
Meta Analysis ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document